Team evitria
Articles written by Team evitria (61)
-
AAX Biotech and evitria to expand access to Opti-mAb® technology in early antibody development
STOCKHOLM / 23 April 2026 – Biotech company AAX Biotech, a leading innovator in technologies for antibody-based therapies, today announced a partnership with evitria AG, an expert provider of antibody engineering and expression services, to enable the use of its Opti-mAb® technology in early…
-
Polyclonal Antibody Production: A Comprehensive Guide
This article will provide a comprehensive guide to polyclonal antibody production (pAb production), outlining the steps involved in the process, discussing the advantages and disadvantages of using polyclonal antibodies, and exploring the alternatives to polyclonal antibody production, including recombinant antibody production.
-
Differences between monoclonal antibodies and recombinant monoclonal antibodies
There are some major differences between monoclonal and recombinant monoclonal antibodies – discover the most important ones in this article!
-
Afucosylated recombinant antibodies
Generally speaking, antibodies of any kind, including recombinant and afucosylated antibodies, are Y-shaped proteins produced by the human body. As they are able to identify and neutralize foreign objects – in other words viruses – they play a major contributing role in keeping our…
-
Bengt Thorsson and Johan Rockberg to join Atlas Antibodies’ Board of Directors
We are pleased to announce the election of Bengt Thorsson and Johan Rockberg to Atlas Antibodies’ Board of Directors, following the AGM on May 23, 2025. Åsa Riisberg has been re-elected as Chair of the Board and Catarina Flyborg, Gavin Wood, Christian Eberle and…
-
Press release: evitria Celebrates 15 Years with Exclusive Giveaway for Industry Experts
Tickets for Festival of Biologics, Networking Dinner, and Exclusive Tour of evitria AG in Zürich Up for Grabs Zurich, Switzerland – March 2025 – evitria, a leading provider of antibody development services, is celebrating its 15th anniversary with an exciting giveaway that offers an…
-
Engineering bispecific antibodies
Recorded Presentation: From mAb to bAb Developing drugs requires navigating complex technical, practical, and strategic challenges quickly. Optimizing a drug’s activity and effectiveness and subsequently considering the IP landscape are crucially important balancing acts. Here, we demonstrate how evitria’s extensive expertise in antibody production…
-
evitria and Lonza Sign License Agreement to Provide Fast Access to bYlok® Bispecific Antibodies for Discovery-Stage Transient Expression Research
Zurich-based evitria AG has entered a non-exclusive license agreement with Lonza for its bYlok® technology, enabling simple and reliable development of IgG-like bispecific antibodies.
-
Transient transfection vs. stable transfection
Both transient and stable transfection are essential methods in genetic engineering. But what are the differences between them? Let’s find out in this article.
-
Benefits of transient transfection
Transient transfection offers numerous advantages in the expression of recombinant proteins. We will uncover the main benefits in this article.
-
How are afucosylated antibodies developed?
Afucosylated antibodies are promising tools in the fight against several diseases. But how are they developed? That is what we are going to find out in this article.
-
Applications of afucosylated antibodies
Afucosylated antibodies are either studied or already used in various fields of application. In this article, we will explore some of them.